Ca++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. I. Characterization of cellular lipid metabolism.
- 1 January 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis: An Official Journal of the American Heart Association, Inc.
- Vol. 8 (1) , 46-56
- https://doi.org/10.1161/01.atv.8.1.46
Abstract
The effects of the slow Ca++ channel blocker, nifedipine, and ACAT inhibitor, octimibate, on the cholesterol metabolism of cholesterol-loaded macrophages were compared. We demonstrated that apolipoprotein A-I containing high density lipoproteins (HDL) bind to specific receptor sites on macrophages, are internalized, take up cholesterol, and are then released from the cells as native lipoproteins. The ACAT inhibitor enhances HDL receptor activity and promotes HDL-mediated cholesterol efflux from cultured mouse peritoneal macrophages. In contrast, the Ca++ antagonist increases acetyl LDL-mediated cholesterol influx, abolishes the increase in HDL binding induced by cholesterol accumulation, enhances apo E synthesis, and promotes cholesterol efflux by a mechanism independent of the presence of HDL in the surrounding medium. Concomitantly, a decrease in nucleoside transporter activity, an increase in intracellular ATP hydrolysis, adenosine and cyclic AMP concentration, and a stimulation of the activities of acid and neutral cholesteryl ester hydrolase and ACAT indicated that protein kinase A-catalyzed phosphorylation reactions might be involved in the increase in cholesterol efflux. The Ca++ antagonist-induced efflux occurred only with lysosomal-associated cholesterol, while the ACAT inhibitor acted on the formation of cytoplasmic lipid droplets. The secreted lipoprotein particles contained 68% unesterified cholesterol and 21% phospholipids, 8% esterified cholesterol, and 3% triglycerides. The phospholipid components were: 72% phosphatidylcholine, 22% sphingomyelin, and 6% phosphatidylserine, phosphatidylinositol, and phosphatidylethanolamine. We conclude that macrophages release cholesterol in two ways: 1) an HDL-mediated release of unesterified cholesterol increasing upon ACAT inhibition, and 2) an HDL-independent secretion of cholesterol which can be amplified by Ca++ antagonists.This publication has 55 references indexed in Scilit:
- [3H]Nitrobenzylthioinosine Binding to the Guinea Pig CNS Nucleoside Transport System: A Pharmacological CharacterizationJournal of Neurochemistry, 1984
- The cholesterol content of the human erythrocyte influences calcium influx through the channelBiochemical and Biophysical Research Communications, 1984
- Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbitThe American Journal of Cardiology, 1984
- Adenosine uptake sites in dog heart and brain; interaction with calcium antagonistsLife Sciences, 1984
- Interactions between adenosine and nifedipine in the rat cerebral cortexNeurochemistry International, 1984
- Slow channel kinetics in heart muscleBasic Research in Cardiology, 1981
- Do benzodiazepines bind at adenosine uptake sites in CNS?Life Sciences, 1981
- Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazemThe American Journal of Cardiology, 1980
- Radioimmunoassay studies of human apolipoprotein E.Journal of Clinical Investigation, 1980
- Activation of adrenal Sterol Ester Hydrolase by dibutyryl cAMP and protein kinaseBiochemical and Biophysical Research Communications, 1974